文献速递类风湿关节炎

类风湿关节炎患者接受Janus激酶抑制剂治疗较生物改善病情抗风湿药心血管事件风险增加:基于日本健康保险数据库的回顾性纵向人群研究

Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database.
PubMed 文献 · RMD Open · 2024-06-17

该回顾性纵向人群研究利用日本理赔数据库,纳入2013年7月至2020年7月间新使用JAK抑制剂、bDMARDs或甲氨蝶呤的成人类风湿关节炎患者53448例,比较心血管事件风险。JAK抑制剂组总体心血管事件发生率高于TNF抑制剂组,校正后HR为1.7(95%CI 1.1-2.5)。作者提示因理赔数据库局限性需谨慎解读。

要点

  • JAK抑制剂组总体心血管事件发生率为10.1/1000患者年,TNF抑制剂组为5.4/1000患者年。
  • JAK抑制剂对比TNF抑制剂(未联用MTX)的校正HR为1.7(95%CI 1.1-2.5)。
  • JAK抑制剂对比TNF抑制剂(联用MTX)的校正HR为1.7(95%CI 1.1-2.7)。

核心结论

  • 在类风湿关节炎患者中,使用JAK抑制剂者总体心血管事件风险显著高于TNF抑制剂使用者,该差异归因于JAK抑制剂与TNF抑制剂相对于MTX的风险差异。
  • 作者提示因理赔数据库相关局限性,这些数据应谨慎解读。

研究设计与样本

  • 回顾性纵向人群研究,使用日本理赔数据库。
  • 纳入标准为至少有一个ICD-10编码(M05或M06)、2013年7月至2020年7月间新使用JAK抑制剂、bDMARDs或MTX、且年龄18岁及以上的类风湿关节炎患者。
  • 共纳入53448例。
  • 计算心血管事件(包括静脉血栓栓塞、动脉血栓形成、急性心肌梗死和卒中)的发生率、发生率比及校正风险比(aHR,95%CI)。
  • 采用时间依赖Cox回归模型,校正基线患者特征以计算aHR。

主要发现

  • 总体心血管事件发生率(/1000患者年)分别为:JAK抑制剂10.1、bDMARDs 6.8、TNF抑制剂5.4、非TNF抑制剂9.1、MTX 11.3。
  • JAK抑制剂对比TNF抑制剂(未联用MTX)的总体心血管事件校正HR为1.7(95%CI 1.1-2.5)。
  • JAK抑制剂对比TNF抑制剂(联用MTX)的总体心血管事件校正HR为1.7(95%CI 1.1-2.7)。

关键数值与推荐

  • 总体心血管事件发生率(/1000患者年):JAK抑制剂10.1、bDMARDs 6.8、TNF抑制剂5.4、非TNF抑制剂9.1、MTX 11.3。
  • JAK抑制剂对比TNF抑制剂(未联用MTX)的总体心血管事件校正HR为1.7(95%CI 1.1-2.5)。
  • JAK抑制剂对比TNF抑制剂(联用MTX)的总体心血管事件校正HR为1.7(95%CI 1.1-2.7)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出因理赔数据库相关局限性,这些数据应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the risk of cardiovascular events among Janus kinase inhibitors (JAKIs), biological disease-modifying antirheumatic drugs (bDMARDs) (tumour necrosis factor inhibitors (TNFIs) and non-TNFIs) and methotrexate (MTX) in Japanese patients with rheumatoid arthritis (RA). METHODS: Using Japanese claims data, patients with RA were enrolled in this study if they had at least one ICD-10 code (M05 or M06), were new users of JAKIs, bDMARDs or MTX between July 2013 and July 2020 and being 18 years old or older. The incidence rate (IR), IR ratio and adjusted hazard ratio (aHR (95% CI)) of cardiovascular events including venous thromboembolism, arterial thrombosis, acute myocardial infarction and stroke were calculated. A time-dependent Cox regression model adjusted for patient characteristics at baseline was used to calculate aHR. RESULTS: In 53 448 cases, IRs/1000 patient-years of the overall cardiovascular events were 10.1, 6.8, 5.4, 9.1 and 11.3 under the treatments with JAKIs, bDMARDs, TNFIs, non-TNFIs and MTX, respectively. The adjusted HRs of JAKIs for overall cardiovascular events were 1.7 (1.1 to 2.5) versus TNFIs without MTX and 1.7 (1.1 to 2.7) versus TNFIs with MTX. CONCLUSIONS: Among patients with RA, individuals using JAKIs had a significantly higher risk of overall cardiovascular events than TNFIs users, which was attributed to the difference in the risk between JAKIs and TNFIs versus MTX. These data should be interpreted with caution because of the limitations associated with the claims database.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Sakai R, Tanaka E, Inoue E, et al. Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database. RMD Open. 2024. PMID: 38886005. doi:10.1136/rmdopen-2023-003885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。